0001213900-26-111756.txt : 20261022 0001213900-26-111756.hdr.sgml : 20261022 20261022172023 ACCESSION NUMBER: 0001213900-26-111756 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20261022 DATE AS OF CHANGE: 20261022 EFFECTIVENESS DATE: 20261022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CollPlant Biotechnologies Ltd CENTRAL INDEX KEY: 0001631487 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-602262 FILM NUMBER: 261479496 BUSINESS ADDRESS: STREET 1: 4 OPPENHEIMER ST., 11TH FLOOR CITY: REHOVOT STATE: L3 ZIP: 74140 BUSINESS PHONE: 972-73-232-5600 MAIL ADDRESS: STREET 1: 4 OPPENHEIMER ST., 11TH FLOOR CITY: REHOVOT STATE: L3 ZIP: 74140 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Holdings Ltd. DATE OF NAME CHANGE: 20190620 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Biotechnologies Ltd. DATE OF NAME CHANGE: 20190619 FORMER COMPANY: FORMER CONFORMED NAME: CollPlant Holdings Ltd. DATE OF NAME CHANGE: 20150122 D 1 primary_doc.xml X0708 D LIVE 0001631487 CollPlant Biotechnologies Ltd 4 OPPENHEIMER, WEIZMANN SCIENCE PARK REHOVOT L3 ISRAEL 7670104 +972 73 232 5600 ISRAEL None CollPlant Holdings Ltd. CollPlant Biotechnologies Ltd. Corporation true Yehiel Tal COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Director Chief Executive Officer and Interim Chairman of the Board of Directors Eran Rotem COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Deputy Chief Executive Officer and Chief Financial Officer Oren Fahimipoor COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Operations Philippe Bensimon COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Regulatory Affairs and Quality Assurance Jasmine Seror COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Product Development Bowman Bagley COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Commercial North America Bar Abelis COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Vice President, Legal Ruti Ben Shlomi COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Executive Officer Director Chief Executive Officer of Lightsolver Ltd., the Issuer's subsidiary. Abraham Havron COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Elan Penn COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Joseph Zarzewsky COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Hugh Evans COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Alisa Lask COLLPLANT BIOTECHNOLOGIES LTD 4 Oppenheimer, Weizmann Science Park Rehovot L3 ISRAEL 7670104 Director Other Health Care Decline to Disclose 06b false 2026-10-09 false true true true true ordinary warrants to purchase ordinary shares, including underlying ordinary shares upon exercise. false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 true Rodman & Renshaw, LLC 000281264 None None 600 Lexington Avenue 32nd Floor New York NY NEW YORK 10022 true 9249958 9249958 0 Including the exercise price of ordinary shares underlying such warrants at an exercise price of $3.74. The total offering amount excludes placement agent warrants (see Item 15). false 5 224000 true 0 Sales Commission includes cash placement fee. Other comp. included management fee, a $35,000 expense allowance, reimbursement of $50,000 for legal fees, $15,950 in clearing fees, and 59,358 warrants with an ex. price of $4.675/share. 0 true The Company intends to use the net proceeds from the Offering for general corporate purposes including working capital and funding its research and development programs. false CollPlant Biotechnologies Ltd /s/ Eran Rotem Eran Rotem Deputy Chief Executive Officer and Chief Financial Officer 2026-10-22